Spots Global Cancer Trial Database for recurrent disease
Every month we try and update this database with for recurrent disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | NCT03643549 | Glioblastoma | Bortezomib and ... Bortezomib and ... | 18 Years - | Haukeland University Hospital | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia | NCT00003145 | Accelerated Pha... Childhood Chron... Chronic Myeloge... Chronic Phase o... Recurrent Disea... | Fludarabine Pho... Total-Body Irra... Nonmyeloablativ... Peripheral Bloo... Cyclosporine Mycophenolate M... Therapeutic All... Laboratory Biom... | - 74 Years | Fred Hutchinson Cancer Center | |
| Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | NCT00249990 | Corpus Uteri Endometrial Can... | 9-NC in aerosol... | 18 Years - | University of New Mexico | |
| A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | NCT05047094 | Head and Neck S... Skin Cancer Metastatic Head... | Diffusing Alpha... Pembrolizumab | 18 Years - | Alpha Tau Medical LTD. | |
| Retreatment With Intratumoral Diffusing Alpha Radiation Emitters | NCT04540588 | Skin Cancer Mucosal Neoplas... Soft Tissue Neo... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas | NCT03591666 | Head and Neck C... Adenocarcinoma Recurrent Disea... Distantly Metas... | Anlotinib | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | NCT03525392 | Pancreatic Duct... Colorectal Canc... Gastric Cancer Squamous Cell C... Bone Cancer Advanced Cancer Recurrent Disea... Metastatic Tumo... | 177Lu-3BP-227 (... | 18 Years - | Ipsen | |
| Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | NCT03792256 | Leukemia, Lymph... Lymphoblastic L... T-cell Lymphoma T-cell Leukemia Recurrent Disea... Acute Leukemia | Palbociclib Cytarabine Methotrexate Hydrocortisone Doxorubicin Prednisolone Vincristine Pegaspargase Hydrocortisone Prednisone | 12 Months - 31 Years | Children's Oncology Group | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN | NCT05260671 | Head and Neck N... Recurrent Disea... Metastatic Canc... | Penpulimab comb... | 18 Years - 80 Years | Eye & ENT Hospital of Fudan University | |
| Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer | NCT00557206 | Neoplasms Head and Neck N... | Oxaliplatin and... | 18 Years - | Minneapolis Veterans Affairs Medical Center | |
| Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence | NCT06088719 | Breast Cancer Recurrent Disea... | axillary surger... | 18 Years - 100 Years | KK Women's and Children's Hospital | |
| Proton Beam Re-Irradiation in Thoracic Cancers | NCT02204761 | Metastatic Mali... Recurrent Disea... Thoracic Neopla... | Proton Beam Rad... | 19 Years - | University of Washington | |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | NCT00383474 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase Recurrent Adult... Recurrent Adult... Recurrent Disea... Untreated Adult... Untreated Adult... | Bortezomib Laboratory Biom... Tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | NCT05588141 | Brain Tumor Cancer | Zotiraciclib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| BIBF 1120 for Recurrent High-Grade Gliomas | NCT01380782 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | BIBF 1120 | 18 Years - | Dana-Farber Cancer Institute | |
| Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs | NCT06014619 | Skin Cancer Complication Complication of... Complication,Po... Recurrence Recurrent Disea... Cutaneous Squam... Basal Cell Carc... Lentigo Maligna Lentigo Maligna... | Mohs surgery Slow Mohs surge... | 16 Years - | Maastricht University Medical Center | |
| Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma | NCT01794845 | Squamous Cell C... Head and Neck C... Recurrent Disea... | Erbitux Taxotere Low Dose Fracti... | - | University of Miami | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | NCT05588141 | Brain Tumor Cancer | Zotiraciclib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | NCT00249990 | Corpus Uteri Endometrial Can... | 9-NC in aerosol... | 18 Years - | University of New Mexico | |
| High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) | NCT04126460 | Head and Neck C... | Toripalimab | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer | NCT00557206 | Neoplasms Head and Neck N... | Oxaliplatin and... | 18 Years - | Minneapolis Veterans Affairs Medical Center | |
| Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts | NCT03415477 | Bone Cyst Aneur... Pathological Fr... Recurrent Disea... Refractory Tumo... | Denosumab (Xgev... | 12 Years - 65 Years | Peking University People's Hospital | |
| Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | NCT03643549 | Glioblastoma | Bortezomib and ... Bortezomib and ... | 18 Years - | Haukeland University Hospital | |
| Efficacy of SU 011248 in Head And Neck Carcinoma | NCT00408252 | Recurrent Disea... Squamous Cell H... Palliative Trea... | biopsies SU011248 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT01445080 | Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea... | Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | NCT00036738 | Adult Acute Lym... Adult B Acute L... Blastic Phase Childhood Acute... Childhood B Acu... Chronic Myeloge... Chronic Phase o... Recurrent Adult... Recurrent Child... Recurrent Disea... | Cyclosporine Dasatinib Fludarabine Pho... Imatinib Mesyla... Mycophenolate M... Nilotinib Nonmyeloablativ... Peripheral Bloo... Therapeutic All... Total-Body Irra... | - 70 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
